Tilray's Beer Bet Just Turned a Profit — and the Market Still Prices It Like a Cannabis Lottery Ticket

Record revenue, BrewDog's first profitable quarter, a Carlsberg deal landing in January — all drowned out by a 35% three-month slide and a 0.6x revenue multiple.

TLRY · Earnings Call · 2026-10-08

The tape and the tale have never diverged wider

Tilray reported a record first-quarter on October 8: net revenue of $257.1 million, up 23% year-over-year, a record first-quarter gross profit of $77.5 million, and consolidated gross margin up roughly 300 basis points to 30%. And yet the stock sits at the bottom of a 0.6x revenue valuation, down 34.8% over the last 90 trading days alone, with the full six-year tape showing a 99.8% drawdown from its 2018 peak. Carl Merton's own summary of the quarter is the whole story: revenue up, margins up, and a $40 million net loss underneath. That gap — between an operating business that is visibly getting healthier and an equity the market treats as a pure-play cannabis option that has expired — is the report.

Beer is where the actual news lives

For years Tilray's beverage segment was the segment analysts apologized for. On this call, it was the headline. BrewDog, acquired out of administration earlier this year, became profitable in Q1 — after what Irwin Simon noted was “at an operating loss for years” — Irwin Simon, CEO · 2026-10-08, per the analyst pressing him. Simon's explanation was characteristically blunt: “I was not saddled with a lot of their bars and pubs that were losing money” — Irwin Simon, CEO · 2026-10-08, plus renegotiated leases, cost discipline, and a World Cup summer. Carl Merton added the detail that matters most for a cash-strapped balance sheet: BrewDog “required no cash injections during the quarter and was self-financing” — Carl Merton, CFO · 2026-10-08. The next leg is Carlsberg. Beginning January 1, 2027, Tilray will brew, market and distribute Carlsberg, Carlsberg Elephant, 1664 and Kronenbourg 1664 Blanc across the entire U.S. This is not a rounding-error deal — Simon frames it as adding “global recognized premium European beer brands” — Irwin Simon, CEO · 2026-10-08 and instant scale to a U.S. business that would otherwise have shrunk this quarter (management conceded beverage revenue would have been down excluding BrewDog — the same admission they made in July when asked about a 17% organic decline, a concern that has now recurred across two consecutive calls). This is also not a Tilray-only theme. In the global keyword set, Beer brand is the number-one market keyword this quarter and Beer company is number two — and Constellation Brands (STZ), which reported the same week, surfaced the same language: Beer Brand, "green shoots," "scale brand." Tilray's own beer brands now tops its internal keyword ranking. Beer is one of the few places where this company is riding a wave rather than fighting one.

The multiple problem management can't stop naming

Simon spent the opening remarks on the one thing he cannot control — how the market reads the ticker.

In the U.S., we continue to believe cannabis reform will create significant opportunities over time... Delays in rescheduling have impacted sentiment towards cannabis stocks, including ours, and we believe the market too often evaluates Tilray as if we are just a pure-play U.S. cannabis operator, but we are not.
Irwin Simon, CEO · 2026-10-08

That is a chairman framing his own diversification as a rescue mission. And to be fair, the platform is real: $222 million of effective net cash, more than $42 million of debt settled fiscal year-to-date, and a leverage ratio of only 31.5% liabilities-to-assets. What is genuinely new in the financial engineering is how Simon reframed the loss. The company carried roughly $5 million of net cash interest in the quarter, and he argued that “without the cash interest, which we are actively working to eliminate, we would have made $2 million of adjusted net income” — Carl Merton, CFO · 2026-10-08. That is a subtle but important pivot: the story is no longer "wait for legalization," it is "wait for us to retire the notes." Cash interest is a brand-new top-five company keyword this quarter — a signal of where management wants investors looking.

Canada shrinks, Europe grows, and the catalyst gets demoted

Strip away the beer and the balance sheet and you find a Canadian business deliberately shrinking. Total cannabis revenue fell to $56.1 million from $64.5 million, with adult-use hurt by strain rotations and roughly one metric ton of inventory redirected to higher-return international markets. Simon's explanation is a rerun of prior quarters — maximize margin, not volume — but the margin defense worked: cannabis gross margin rose ~300bp to 39% even against $8.8 million of international price compression. The growth engine is the same one Tilray has touted for a year: International cannabis revenue up 21%, EMEA up over 70%, Portugal flower volumes up 110%. The patient access theme — Lyphe in the U.K., CC Pharma's 16,000 German pharmacies — is the durable moat management keeps pointing to, now a top-five company keyword for the first time. Notably absent in force: the U.S. rescheduling catalyst. A year ago this was a headline theme with its own keyword tier; now Simon explicitly demotes it — “our strategy is not dependent upon 1 regulatory event” — Irwin Simon, CEO · 2026-10-08. When a CEO stops leaning on a catalyst, that de-risking is itself the message.

Caveats worth flagging

The fundamentals here are a quarter stale — 32.1% gross margin and 2.3x gross profit reflect the fiscal Q4 filing, not the October call. Still, the trajectory holds: gross margin has clawed back from the negative prints of the HEXO write-down era, and free cash flow remains negative. If BrewDog is genuinely self-funding and Carlsberg lands in January, the cash math could finally inflect in 2027. If not, an 84%-below-high equity with a 0.6x multiple tells you precisely what the market believes. The beer turned a profit; the story has not yet turned the tape.